Unknown PHASE2 INTERVENTIONAL 1-arm NCT03923166

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer: Single Arm, Single Center, Phase II Clinical Trial.

Sponsor: Chinese Academy of Medical Sciences

Conditions Breast Cancer

Interventions Pyrotinib capecitabine

Updated 7 times since 2019 Last updated: Apr 19, 2019 Started: Apr 19, 2019 Primary completion: Apr 1, 2021 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and is currently ongoing. Chinese Academy of Medical Sciences leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status PHASE2
Dec 2022 — Oct 2023 [monthly]

Unknown Status PHASE2
Jan 2022 — Dec 2022 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE2
May 2019 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Academy of Medical Sciences

Data source: ChineseAMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China